Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by mikeq113on Jan 21, 2022 1:48pm
113 Views
Post# 34343715

RE:RE:RE:RE:RE:RE:RE:RE:Friday or 4pm NR is better

RE:RE:RE:RE:RE:RE:RE:RE:Friday or 4pm NR is better

It seems a little more defined when re-reading the transcript from the last update (about 14 weeks ago). Christian specifically stated During the Q&A that each cycle is 3 weeks; however it's closer to 5 or 6 weeks when considering that they need to gather the necessary data before moving forward with the next dose. If that's the case then we're really not that far off. 

Unfortunately, within the same breath he also referenced end of year (2021) as the potential point at which they could reach their MTD then moving on to the basket trial by early 2022 and also made mention of only needing a few more patients.

Again, it's rather muddy at best but it doesn't seem to be at a point where we really need to sound the alarm. Maybe I'm wrong though.  

<< Previous
Bullboard Posts
Next >>